These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1116 related articles for article (PubMed ID: 11118060)

  • 1. HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice.
    Kuba K; Matsumoto K; Date K; Shimura H; Tanaka M; Nakamura T
    Cancer Res; 2000 Dec; 60(23):6737-43. PubMed ID: 11118060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HGF/NK4 inhibited VEGF-induced angiogenesis in in vitro cultured endothelial cells and in vivo rabbit model.
    Nakabayashi M; Morishita R; Nakagami H; Kuba K; Matsumoto K; Nakamura T; Tano Y; Kaneda Y
    Diabetologia; 2003 Jan; 46(1):115-23. PubMed ID: 12637990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kringle 1-4 of hepatocyte growth factor inhibits proliferation and migration of human microvascular endothelial cells.
    Kuba K; Matsumoto K; Ohnishi K; Shiratsuchi T; Tanaka M; Nakamura T
    Biochem Biophys Res Commun; 2000 Dec; 279(3):846-52. PubMed ID: 11162438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
    Qian F; Engst S; Yamaguchi K; Yu P; Won KA; Mock L; Lou T; Tan J; Li C; Tam D; Lougheed J; Yakes FM; Bentzien F; Xu W; Zaks T; Wooster R; Greshock J; Joly AH
    Cancer Res; 2009 Oct; 69(20):8009-16. PubMed ID: 19808973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of growth, invasion, and metastasis of human pancreatic carcinoma cells by NK4 in an orthotopic mouse model.
    Tomioka D; Maehara N; Kuba K; Mizumoto K; Tanaka M; Matsumoto K; Nakamura T
    Cancer Res; 2001 Oct; 61(20):7518-24. PubMed ID: 11606388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatic gene expression of NK4, an HGF-antagonist/angiogenesis inhibitor, suppresses liver metastasis and invasive growth of colon cancer in mice.
    Wen J; Matsumoto K; Taniura N; Tomioka D; Nakamura T
    Cancer Gene Ther; 2004 Jun; 11(6):419-30. PubMed ID: 15017381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of tumor growth and invasion by a four-kringle antagonist (HGF/NK4) for hepatocyte growth factor.
    Date K; Matsumoto K; Kuba K; Shimura H; Tanaka M; Nakamura T
    Oncogene; 1998 Dec; 17(23):3045-54. PubMed ID: 9881707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.
    Sun J; Blaskovich MA; Jain RK; Delarue F; Paris D; Brem S; Wotoczek-Obadia M; Lin Q; Coppola D; Choi K; Mullan M; Hamilton AD; Sebti SM
    Cancer Res; 2004 May; 64(10):3586-92. PubMed ID: 15150116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antagonistic effect of NK4, a novel hepatocyte growth factor variant, on in vitro angiogenesis of human vascular endothelial cells.
    Jiang WG; Hiscox SE; Parr C; Martin TA; Matsumoto K; Nakamura T; Mansel RE
    Clin Cancer Res; 1999 Nov; 5(11):3695-703. PubMed ID: 10589789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms and significance of bifunctional NK4 in cancer treatment.
    Matsumoto K; Nakamura T
    Biochem Biophys Res Commun; 2005 Jul; 333(2):316-27. PubMed ID: 15950947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor suppression through angiogenesis inhibition by SUIT-2 pancreatic cancer cells genetically engineered to secrete NK4.
    Saimura M; Nagai E; Mizumoto K; Maehara N; Minamishima YA; Katano M; Matsumoto K; Nakamura T; Tanaka M
    Clin Cancer Res; 2002 Oct; 8(10):3243-9. PubMed ID: 12374695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of tumor growth, invasion and angiogenesis of human gastric cancer by adenovirus-mediated expression of NK4.
    Heideman DA; van Beusechem VW; Bloemena E; Snijders PJ; Craanen ME; Offerhaus GJ; Derksen PW; de Bruin M; Witlox MA; Molenaar B; Meijer CJ; Gerritsen WR
    J Gene Med; 2004 Mar; 6(3):317-27. PubMed ID: 15026993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of intracerebral glioblastoma growth by local treatment with the scatter factor/hepatocyte growth factor-antagonist NK4.
    Brockmann MA; Papadimitriou A; Brandt M; Fillbrandt R; Westphal M; Lamszus K
    Clin Cancer Res; 2003 Oct; 9(12):4578-85. PubMed ID: 14555533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatocyte growth factor and Met in tumor biology and therapeutic approach with NK4.
    Matsumoto K; Nakamura T; Sakai K; Nakamura T
    Proteomics; 2008 Aug; 8(16):3360-70. PubMed ID: 18646008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
    Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
    Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclooxygenase-2-selective nonsteroidal anti-inflammatory drugs inhibit hepatocyte growth factor/scatter factor-induced angiogenesis.
    Sengupta S; Sellers LA; Cindrova T; Skepper J; Gherardi E; Sasisekharan R; Fan TP
    Cancer Res; 2003 Dec; 63(23):8351-9. PubMed ID: 14678996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation.
    Yano S; Herbst RS; Shinohara H; Knighton B; Bucana CD; Killion JJ; Wood J; Fidler IJ
    Clin Cancer Res; 2000 Mar; 6(3):957-65. PubMed ID: 10741721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function.
    Mendel DB; Schreck RE; West DC; Li G; Strawn LM; Tanciongco SS; Vasile S; Shawver LK; Cherrington JM
    Clin Cancer Res; 2000 Dec; 6(12):4848-58. PubMed ID: 11156244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intraperitoneal injection of adenovirus-mediated NK4 gene suppresses peritoneal dissemination of pancreatic cancer cell line AsPC-1 in nude mice.
    Saimura M; Nagai E; Mizumoto K; Maehara N; Okino H; Katano M; Matsumoto K; Nakamura T; Narumi K; Nukiwa T; Tanaka M
    Cancer Gene Ther; 2002 Oct; 9(10):799-806. PubMed ID: 12224019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 56.